LENZ Therapeutics was founded with a strategic focus on developing innovative, non-invasive ophthalmic pharmaceutical products designed to address widespread vision impairments. The company advanced its lead therapeutic candidate—an advanced aceclidine-based eye drop targeting presbyopia—through comprehensive preclinical development and successful pivotal clinical trials, culminating in regulatory submission, U.S. Food and Drug Administration approval, and a subsequent public listing on the Nasdaq exchange to accelerate commercial distribution.